Robert John Fontana, MD
Professor
Email:
[email protected]
Available to mentor
Robert John Fontana, MD
Professor
Manage Your Profile
Qualifications
-
Fellow, GastroenterologyUniversity of Michigan, Ann Arbor, Michigan
1992 - 1995
-
Chief Medical ResidentSt. Joseph Hospital, Chicago, Illinois
1991 - 1992
-
Residency, Internal MedicineNorthwestern University, Chicago, Illinois
1988 - 1991
-
B.S. ChemistryWayne State University, Detroit, Michigan
1980 - 1984
Recent Publications
-
Bogdanov JM, Zhao N, Alavifard H, Kleiner DE, Fontana RJ, Stolz¹ AA, Merchant A, Sexton JZ, Dara L. 2026 Aug 23; medRxiv,PreprintMacrophage-CD8⁺ T Cell Spatial Coupling Defines an Innate-Adaptive Injury Niche in Human Checkpoint Inhibitor Hepatotoxicity
DOI:10.64898/2026.08.18.26360744 -
Meunier L, Kleiner DE, Riviere B, Barnhart H, Kamusiime R, Chen VL, Larrey D, Fontana RJ. Hepatology Communications, 2026 Aug 1; 10 (8):Journal ArticleLiver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors
DOI:10.1097/HC9.0000000000000988 PMID: 42486793 -
Swanson L, Fontana RJ. Hepatology Communications, 2026 Aug 1; 10 (8):Journal ArticleThe contemporary epidemiology, causes, and management of drug-induced liver injury
DOI:10.1097/HC9.0000000000001011 PMID: 42475234 -
Robert A, Bhave N, Christensen J, Sheetz K, Tomm N, Fontana RJ. Frontiers in Transplantation, 2026 Jun 1; 5:Journal ArticleHepatic adenomatosis leading to liver failure and symptomatic extrinsic cardiac compression treated with liver transplantation: a case report and literature review
DOI:10.3389/frtra.2026.1810971 -
Arab JP, Malhi H, Winder GS, Fontana RJ. Clinical Gastroenterology and Hepatology, 2026 Jan 1;Journal ArticleAGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction– and Alcohol-Associated Liver Disease: Expert Review
DOI:10.1016/j.cgh.2026.07.027 PMID: 42776095 -
Fontana RJ, Likhitsup A. Clinical Gastroenterology and Hepatology, 2026 Jan 1;Journal ArticleReply
DOI:10.1016/j.cgh.2026.01.003 PMID: 41544835 -
Lammert CS, Weinberg EM, Sclair SN, Fontana RJ, Anand NK, Anderl JL, Bade D, Desai S, Kirk CJ, Lam D, Lowe E, Muchamuel T, Palaniswamy K, Peterson R, Ray K, To Z, Tuch BB, Whang JA, Goel A. Hepatology, 2026 Jan 1;Journal ArticleSafety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension
DOI:10.1097/HEP.0000000000001840 PMID: 42770396 -
Borchert JA, Remih K, Lee WM, Fontana RJ, Strnad P. Zeitschrift für Gastroenterologie, 2025 Sep 5; 63 (08): e449 - e449.Proceeding / Abstract / PosterPrognostischer Wert von Hepcidin in Patienten mit akutem Leberversagen
DOI:10.1055/s-0045-1810763
Featured News & Stories
Health Lab
Evolving causes, diagnosis of drug-induced liver injury
The causes of drug-induced liver injury have evolved over the last 20 years, according to a review in Hepatology Communications.
Health Lab
What to know about a benign liver cyst on your imaging results
Abdominal imaging may sometimes mark an alarming “benign-appearing cyst” on the liver, but a Michigan Medicine expert explains why many times you don't need to worry.
Health Lab
New metric better predicts which drug-induced liver injury patients require transplant
Study finds the DILI-Inpt prognostic score outperformed existing systems in identifying which hospitalized patients with severe idiosyncratic drug-induced liver injury were unlikely to recover on their own.
Department News
CME Event - 28th Annual Liver Disease Wrap-Up
Join us for the 28th Annual Liver Disease Wrap-Up, taking place on Saturday, December 6, 2025, from 8:00am - 12:15 pm at the Detroit Marriott Livonia, Livonia, MI.
Department News
27th Annual Liver Disease Wrap-Up
Join us for the 27th Annual Liver Disease Wrap-Up conference taking place on Saturday, December 7, 2024
Health Lab
How do GLP-1 weight loss drugs affect the liver?
Glucagon-like peptide-1, or GLP-1, receptor agonists, that aid in weight loss, are now being investigated for their ability to help other patients, including those with liver disease. However, a research letter discusses the first known case of hepatitis and jaundice in a patient taking these drugs.